Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma
Anna Lundahl, J Grigg, Lubna Abuqayyas, Piotr Kuna et autres
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in …
se, gb, us, ch, pl, Afrique du Sud, fi, it (code pays fourni par la source)
0 citations
British Journal of Clinical Pharmacology